WCM Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

WCM Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26,997	Closed	-$2.72M	–	218
2021 Q3	$2.72M	Buy	26,997 +421	+2%	+$49.3K	0.01%	163
2021 Q2	$3.76M	Sell	26,576 -14,383	-35%	-$1.62M	0.01%	146
2021 Q1	$4.08M	Buy	40,959 +14,647	+56%	+$1.71M	0.01%	142
2020 Q4	$3.25M	Buy	26,312 +116	+0.4%	+$15.2K	0.01%	153
2020 Q3	$2.55M	Buy	26,196 +1,541	+6%	+$193K	0.01%	152
2020 Q2	$3.85M	Buy	24,655 +12,773	+107%	+$1.94M	0.01%	139
2020 Q1	$1.72M	Buy	11,882 +3,463	+41%	+$669K	0.01%	152
2019 Q4	$1.72M	Buy	8,419 +2,110	+33%	+$385K	0.01%	147
2019 Q3	$507K	Sell	6,309 -2,220	-26%	-$188K	﹤0.01%	142
2019 Q2	$804K	Sell	8,529 -273	-3%	-$23.6K	0.01%	134
2019 Q1	$752K	Buy	+8,802	New	+$731K	0.01%	128

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

WCM Investment Management's RETA Position: Q4 2021 in Review

WCM Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 26,997 shares — an estimated $2.72M sold.

WCM Investment Management first reported a position in RETA in Q1 2019 and held it in 11 quarters. The position peaked at $4.08M in Q1 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

WCM Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
WCM Investment Management sold 26,997 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $2.72M.
WCM Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 11 quarters.
WCM Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.08M in Q1 2021.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on WCM Investment Management's 13F filing for Q4 2021, filed 26 Jan 2022.